ING Groep NV trimmed its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 19.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 53,538 shares of the pharmaceutical company’s stock after selling 12,587 shares during the period. ING Groep NV’s holdings in Vertex Pharmaceuticals were worth $24,899,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. Northwest Investment Counselors LLC bought a new stake in Vertex Pharmaceuticals in the third quarter valued at approximately $25,000. Highline Wealth Partners LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter worth $27,000. GHP Investment Advisors Inc. acquired a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at approximately $29,000. Stephens Consulting LLC acquired a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter valued at $31,000. Finally, Founders Capital Management lifted its stake in Vertex Pharmaceuticals by 50.0% in the 2nd quarter. Founders Capital Management now owns 75 shares of the pharmaceutical company’s stock valued at $35,000 after purchasing an additional 25 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors.
Vertex Pharmaceuticals Trading Down 0.5 %
NASDAQ VRTX traded down $2.50 during mid-day trading on Thursday, hitting $492.11. The company’s stock had a trading volume of 280,497 shares, compared to its average volume of 1,168,840. The firm has a market capitalization of $126.73 billion, a P/E ratio of -248.55 and a beta of 0.39. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20. Vertex Pharmaceuticals Incorporated has a 52-week low of $341.90 and a 52-week high of $519.88. The stock’s fifty day simple moving average is $476.13 and its two-hundred day simple moving average is $470.48.
Insider Transactions at Vertex Pharmaceuticals
In related news, Chairman Jeffrey M. Leiden sold 3,784 shares of Vertex Pharmaceuticals stock in a transaction on Friday, August 30th. The shares were sold at an average price of $499.00, for a total value of $1,888,216.00. Following the transaction, the chairman now owns 9,994 shares in the company, valued at $4,987,006. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 3,784 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $499.00, for a total transaction of $1,888,216.00. Following the transaction, the chairman now owns 9,994 shares of the company’s stock, valued at approximately $4,987,006. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Sangeeta N. Bhatia sold 646 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $500.00, for a total value of $323,000.00. Following the completion of the sale, the director now owns 4,435 shares of the company’s stock, valued at $2,217,500. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by insiders.
Analysts Set New Price Targets
A number of equities research analysts have commented on the company. TD Cowen raised their price objective on Vertex Pharmaceuticals from $450.00 to $500.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Canaccord Genuity Group lifted their price objective on shares of Vertex Pharmaceuticals from $361.00 to $408.00 and gave the stock a “sell” rating in a research report on Wednesday, November 6th. Royal Bank of Canada boosted their price objective on shares of Vertex Pharmaceuticals from $437.00 to $451.00 and gave the company a “sector perform” rating in a research note on Tuesday, November 5th. Needham & Company LLC reissued a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Friday, July 26th. Finally, Citigroup began coverage on Vertex Pharmaceuticals in a research note on Thursday. They issued a “buy” rating and a $575.00 price target on the stock. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $499.12.
Get Our Latest Stock Analysis on Vertex Pharmaceuticals
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
See Also
- Five stocks we like better than Vertex Pharmaceuticals
- What is Insider Trading? What You Can Learn from Insider Trading
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- What are earnings reports?
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.